Compile Data Set for Download or QSAR
Report error Found 1761 for UniProtKB: P51946
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583927(CHEMBL5088381)
Affinity DataKd:  0.0300nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583928(CHEMBL5080711)
Affinity DataKd:  0.0600nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583918(CHEMBL4791134)
Affinity DataKd:  0.0700nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583929(Sy 5609 | Sy-5609 | SY5609 | SY-5609)
Affinity DataKd:  0.0700nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583923(CHEMBL4786592)
Affinity DataKd:  0.0800nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583925(CHEMBL4782954)
Affinity DataKd:  0.0800nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583919(CHEMBL5083688)
Affinity DataKd:  0.0900nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583921(CHEMBL4779443)
Affinity DataKd:  0.100nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583924(CHEMBL4790490)
Affinity DataKd:  0.100nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583926(CHEMBL4798916)
Affinity DataKd:  0.150nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583916(CHEMBL4786320)
Affinity DataKd:  0.150nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583922(CHEMBL4786555)
Affinity DataKd:  0.210nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50526790(CHEMBL4555799)
Affinity DataKd:  0.330nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583920(CHEMBL4786843)
Affinity DataKd:  0.340nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50583917(CHEMBL4800180)
Affinity DataKd:  0.400nMAssay Description:Binding affinity to full length CDK7 (1 to 346 residues) /N-terminal TEV cleavable 6His tagged full length cyclinH (1 to 323 residues) (unknown origi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM7533(2,6,9-Trisubstituted purine deriv. 28 | (2R)-2-[[6...)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of CDK7/Cyclin H (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.623nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.996nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.996nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.996nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730258(US20250109156, Compound 1)
Affinity DataIC50: 1nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730259(US20250109156, Compound 3)
Affinity DataIC50: 1.10nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730299(US20250109156, Compound 5)
Affinity DataIC50: 1.20nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50553499(CHEMBL4754493)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of CDK7/Cyclin H (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM50539763(Adagrasib | Mrtx-849 | Mrtx849)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of CDK7/Cyclin H/MAT1 (unknown origin) in leukemia cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
PubMed
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530357(WO2022064009, Compound 148 | WO2022064009, Compoun...)
Affinity DataIC50: 1.38nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730300(US20250109156, Compound 6)
Affinity DataIC50: 1.40nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530269(WO2022064009, Compound 13)
Affinity DataIC50: 1.41nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730298(US20250109156, Compound 4)
Affinity DataIC50: 1.60nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530396(WO2022064009, Compound 173)
Affinity DataIC50: 1.66nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530309(WO2022064009, Compound 70)
Affinity DataIC50: 1.78nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50193093(RGB-286638)
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK7/cyclin H (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530370(WO2022064009, Compound 180a)
Affinity DataIC50: 2.09nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530249(WO2022064009, Compound 5)
Affinity DataIC50: 2.14nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530318(WO2022064009, Compound 91 | WO2022064009, Compound...)
Affinity DataIC50: 2.14nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530318(WO2022064009, Compound 91 | WO2022064009, Compound...)
Affinity DataIC50: 2.14nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM669853(US20240132489, Compound 27 | (S)-4-(6-(3,6-dihydro...)
Affinity DataIC50: 2.17nMAssay Description:The test was performed in a U-shaped bottom 384-well plate (coming, 4512 #), and the reaction temperature was 27° C. CDK7/CyclinH was diluted in a te...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2024
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530297(WO2022064009, Compound 58)
Affinity DataIC50: 2.34nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530245(WO2022064009, Compound 51 | WO2022064009, Compound...)
Affinity DataIC50: 2.45nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530266(WO2022064009, Compound 154 | WO2022064009, Compoun...)
Affinity DataIC50: 2.51nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530260(WO2022064009, Compound 37)
Affinity DataIC50: 2.51nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530383(WO2022064009, Compound 160)
Affinity DataIC50: 2.63nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530397(WO2022064009, Compound 174)
Affinity DataIC50: 2.63nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530252(WO2022064009, Compound 8)
Affinity DataIC50: 2.69nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530308(WO2022064009, Compound 69)
Affinity DataIC50: 2.69nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Syros Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM669874(US20240132489, Compound Mixture 105 and 106)
Affinity DataIC50: 2.70nMAssay Description:The test was performed in a U-shaped bottom 384-well plate (coming, 4512 #), and the reaction temperature was 27° C. CDK7/CyclinH was diluted in a te...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2024
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM530305(WO2022064009, Compound 66)
Affinity DataIC50: 2.75nMAssay Description:Inhibition potencies of compounds were studied using an absorbance kinetic assay as described below. Absorbance kinetic assay (5 nM CDK7/Cyclin H/MAT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
WIPO WO2022064009

Displayed 1 to 50 (of 1761 total ) | Next | Last >>
Jump to: